A new antibody shot that protects babies against RSV infection could be struggling to gain traction, researchers report.

Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...

Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...

Shifts in RSV testing methodology, which were accelerated by changes related to the COVID-19 pandemic, mirror shifts seen in ...

GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...

Researchers at MIT and other institutions have identified compounds that can fight off viral infection by activating a ...

MIT researchers identified compounds that can fight off viral infection by activating a defense pathway inside host cells. These compounds could be used as antiviral drugs that work against not just ...

RSV is a major cause of morbidity and a large public health threat, yet its burden in Asia remains poorly characterized, limiting effective public health planning. This study's objectives were to ...